Figure 4.
Circulating cytokine and metabolite modification induced by different LD regimens. (A) Schematic of experimental design; patients undergoing CART19 are recruited for serum samples before LD start (Pre-LD: Flu/Cy at day –5; Benda at day –4) and before CART19 infusion (same day, Post-LD). Matched serum samples were then analyzed for cytokines through Luminex immunoassay and metabolomic through HPLC/MS. (B) Heat map shows different median cytokines level changes from pre-LD values to after LD according to the different LD regimens. Cytokines are listed in decrescent order of median fold change in patients treated with Flu/Cy. (C) Heat map shows different median metabolite level changes from pre-LD values to after LD according to the different LD regimens. Metabolites are listed in decrescent order of differences of median fold change in patients treated with Flu/Cy vs those treated with Benda. ∗P < .050. HPLC/MS, high-performance liquid chromatography/mass spectrometry.

Circulating cytokine and metabolite modification induced by different LD regimens. (A) Schematic of experimental design; patients undergoing CART19 are recruited for serum samples before LD start (Pre-LD: Flu/Cy at day –5; Benda at day –4) and before CART19 infusion (same day, Post-LD). Matched serum samples were then analyzed for cytokines through Luminex immunoassay and metabolomic through HPLC/MS. (B) Heat map shows different median cytokines level changes from pre-LD values to after LD according to the different LD regimens. Cytokines are listed in decrescent order of median fold change in patients treated with Flu/Cy. (C) Heat map shows different median metabolite level changes from pre-LD values to after LD according to the different LD regimens. Metabolites are listed in decrescent order of differences of median fold change in patients treated with Flu/Cy vs those treated with Benda. ∗P < .050. HPLC/MS, high-performance liquid chromatography/mass spectrometry.

Close Modal

or Create an Account

Close Modal
Close Modal